AstraZeneca Pharma India Limited will launch durvalumab (Imfinzi™) in India on October 22, 2019.
Durvalumab (Imfinzi™) provides a treatment option for patients with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.
Durvalumab (Imfinzi™) is a product of AstraZeneca global. As of April 30, 2019, durvalumab is approved in 18 countries for urothelial cancer and over 30 countries for NSCLC including US, EU, Japan and Brazil.
The company has already received Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for durvalumab (Imfinzi™).
Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.2275.85 as compared to the previous close of Rs. 2299.5. The total number of shares traded during the day was 670 in over 177 trades.
The stock hit an intraday high of Rs. 2331.25 and intraday low of 2265. The net turnover during the day was Rs. 1536907.